CA3002544C - 5-ht2c receptor agonists and compositions and methods of use - Google Patents
5-ht2c receptor agonists and compositions and methods of use Download PDFInfo
- Publication number
- CA3002544C CA3002544C CA3002544A CA3002544A CA3002544C CA 3002544 C CA3002544 C CA 3002544C CA 3002544 A CA3002544 A CA 3002544A CA 3002544 A CA3002544 A CA 3002544A CA 3002544 C CA3002544 C CA 3002544C
- Authority
- CA
- Canada
- Prior art keywords
- individual
- compound
- pharmaceutically acceptable
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153082P | 2015-04-27 | 2015-04-27 | |
| US62/153,082 | 2015-04-27 | ||
| PCT/US2016/029308 WO2016176177A1 (en) | 2015-04-27 | 2016-04-26 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3002544A1 CA3002544A1 (en) | 2016-11-03 |
| CA3002544C true CA3002544C (en) | 2024-03-05 |
Family
ID=55949111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3002544A Active CA3002544C (en) | 2015-04-27 | 2016-04-26 | 5-ht2c receptor agonists and compositions and methods of use |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10392390B2 (https=) |
| EP (1) | EP3288946B1 (https=) |
| JP (1) | JP6675688B2 (https=) |
| KR (1) | KR102275505B1 (https=) |
| CN (1) | CN107873030B (https=) |
| AU (1) | AU2016255009B2 (https=) |
| BR (1) | BR112017023088B1 (https=) |
| CA (1) | CA3002544C (https=) |
| DK (1) | DK3288946T3 (https=) |
| EA (1) | EA034446B1 (https=) |
| ES (1) | ES2757922T3 (https=) |
| HK (1) | HK1244005B (https=) |
| HR (1) | HRP20192044T1 (https=) |
| HU (1) | HUE047169T2 (https=) |
| IL (1) | IL255171A0 (https=) |
| MX (2) | MX373319B (https=) |
| PT (1) | PT3288946T (https=) |
| WO (1) | WO2016176177A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
| EP3746126B1 (en) | 2018-01-30 | 2024-07-31 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea or simple snoring |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP4635514A3 (en) * | 2019-02-08 | 2025-12-24 | The Brigham & Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| US12205686B2 (en) * | 2020-02-27 | 2025-01-21 | The Cleveland Clinic Foundation | Identifying patients for intensive hyperglycemia management |
| US20250073206A1 (en) * | 2021-10-29 | 2025-03-06 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| JP2024546484A (ja) * | 2021-12-10 | 2024-12-24 | ジーエーティーシー ヘルス コーポレーション | 中毒および神経障害を治療する方法 |
| CA3254932A1 (en) * | 2022-03-10 | 2023-09-14 | Arena Pharmaceuticals, Inc. | TREATMENT METHODS |
| CN114965250B (zh) * | 2022-05-19 | 2025-02-14 | 道生天合材料科技(上海)股份有限公司 | 胶粘剂储存期的预测方法 |
| WO2023225773A1 (en) * | 2022-05-23 | 2023-11-30 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| EP4626437A1 (en) | 2022-12-02 | 2025-10-08 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| WO2024173626A1 (en) * | 2023-02-17 | 2024-08-22 | Caamtech, Inc. | 2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride |
| CN121127458A (zh) * | 2023-03-02 | 2025-12-12 | 亚历山大舒尔金研究所有限公司 | 苯烷胺前药 |
| TW202529748A (zh) * | 2023-10-11 | 2025-08-01 | 義大利帕多瓦大學 | 使用賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）及賽洛辛（ｐｓｉｌｏｃｉｎ）衍生物之治療方法 |
| US20260048069A1 (en) | 2024-07-26 | 2026-02-19 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| WO2026043678A1 (en) | 2024-08-23 | 2026-02-26 | Arena Pharmaceuticals, Inc. | Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy |
| US20260091039A1 (en) | 2024-10-01 | 2026-04-02 | Arena Pharmaceuticals, Inc. | Hydrochloric acid salt of a 5-ht2c agonist |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642822A (en) * | 1969-11-03 | 1972-02-15 | Upjohn Co | Hexahydropyrrolobenzodiazepines |
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4920989A (en) | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| US5004610A (en) | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| WO1992018005A1 (en) | 1991-04-16 | 1992-10-29 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| ES2230382T3 (es) * | 2000-11-03 | 2005-05-01 | Wyeth | Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c. |
| AU2002227170A1 (en) * | 2000-11-03 | 2002-05-15 | Wyeth | Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives |
| AU2003228485A1 (en) | 2002-04-12 | 2003-10-27 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| TW200307540A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
| CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| TW200806321A (en) * | 2006-03-24 | 2008-02-01 | Wyeth Corp | New therapeutic combinations for the treatment or prevention of psychotic disorders |
| US9556200B2 (en) * | 2012-03-06 | 2017-01-31 | Takeda Pharmaceutical Company Limited | Tricyclic compound |
| SG11201501894VA (en) * | 2012-09-14 | 2015-04-29 | Abbvie Inc | Tricyclic quinoline and quinoxaline derivatives |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
-
2016
- 2016-04-26 DK DK16721320T patent/DK3288946T3/da active
- 2016-04-26 BR BR112017023088-7A patent/BR112017023088B1/pt active IP Right Grant
- 2016-04-26 PT PT167213206T patent/PT3288946T/pt unknown
- 2016-04-26 US US15/567,116 patent/US10392390B2/en active Active
- 2016-04-26 WO PCT/US2016/029308 patent/WO2016176177A1/en not_active Ceased
- 2016-04-26 HU HUE16721320A patent/HUE047169T2/hu unknown
- 2016-04-26 EP EP16721320.6A patent/EP3288946B1/en active Active
- 2016-04-26 CA CA3002544A patent/CA3002544C/en active Active
- 2016-04-26 CN CN201680037275.XA patent/CN107873030B/zh active Active
- 2016-04-26 EA EA201792356A patent/EA034446B1/ru not_active IP Right Cessation
- 2016-04-26 MX MX2017013902A patent/MX373319B/es active IP Right Grant
- 2016-04-26 JP JP2017555768A patent/JP6675688B2/ja active Active
- 2016-04-26 ES ES16721320T patent/ES2757922T3/es active Active
- 2016-04-26 HR HRP20192044TT patent/HRP20192044T1/hr unknown
- 2016-04-26 KR KR1020177033892A patent/KR102275505B1/ko active Active
- 2016-04-26 AU AU2016255009A patent/AU2016255009B2/en active Active
- 2016-04-26 HK HK18103485.6A patent/HK1244005B/en unknown
-
2017
- 2017-10-22 IL IL255171A patent/IL255171A0/en active IP Right Grant
- 2017-10-27 MX MX2020005898A patent/MX2020005898A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE047169T2 (hu) | 2020-04-28 |
| US10392390B2 (en) | 2019-08-27 |
| EA201792356A1 (ru) | 2018-05-31 |
| BR112017023088A2 (pt) | 2018-07-10 |
| PT3288946T (pt) | 2019-11-27 |
| JP6675688B2 (ja) | 2020-04-01 |
| IL255171A0 (en) | 2017-12-31 |
| US20180186797A1 (en) | 2018-07-05 |
| CN107873030B (zh) | 2021-03-19 |
| BR112017023088B1 (pt) | 2023-10-03 |
| MX373319B (es) | 2020-06-13 |
| MX2020005898A (es) | 2020-08-13 |
| ES2757922T3 (es) | 2020-04-30 |
| WO2016176177A1 (en) | 2016-11-03 |
| EP3288946A1 (en) | 2018-03-07 |
| JP2018519251A (ja) | 2018-07-19 |
| KR20170140317A (ko) | 2017-12-20 |
| HRP20192044T1 (hr) | 2020-02-07 |
| CN107873030A (zh) | 2018-04-03 |
| CA3002544A1 (en) | 2016-11-03 |
| EA034446B1 (ru) | 2020-02-10 |
| NZ737412A (en) | 2021-06-25 |
| KR102275505B1 (ko) | 2021-07-08 |
| AU2016255009A1 (en) | 2017-12-14 |
| AU2016255009B2 (en) | 2020-10-08 |
| EP3288946B1 (en) | 2019-08-21 |
| HK1244005B (en) | 2020-04-17 |
| MX2017013902A (es) | 2018-03-16 |
| DK3288946T3 (da) | 2019-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3002544C (en) | 5-ht2c receptor agonists and compositions and methods of use | |
| US11395824B2 (en) | 5-HT2C receptor agonists and compositions and methods of use | |
| HK1244005A1 (en) | 5-ht2c receptor agonists and compositions and methods of use | |
| US11608339B2 (en) | 5-HT2C receptor agonists and compositions and methods of use | |
| WO2015066344A1 (en) | 5-ht2c receptor agonists and compositions and methods of use | |
| JP2018519251A5 (https=) | ||
| NZ737412B2 (en) | 5-ht2c receptor agonists and compositions and methods of use | |
| NZ739883B2 (en) | 5-ht2c receptor agonists and compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210419 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250409 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |